Yahoo Finance

Minghui and Qilu Pharmaceutical to advance MHB088C in Greater China

Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for developing, manufacturing, and commercialising MHB088C in Greater China. Under the ...
Yahoo Finance

Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu ...

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO ...

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 15, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative ...
BioWorld

Qilu nabs China rights to Minghui’s B7-H3 ADC for up to $186M

Minghui Pharmaceutical Ltd. is out-licensing its antibody-drug conjugate (ADC) MHB-088C to Qilu Pharmaceutical Co. Ltd. for China rights for up to ¥1.345 billion (US$186.44 million). Under terms of ...